2010
Expanded HIV Screening in the United States: What Will It Cost Government Discretionary and Entitlement Programs? A Budget Impact Analysis
Martin EG, Paltiel AD, Walensky RP, Schackman BR. Expanded HIV Screening in the United States: What Will It Cost Government Discretionary and Entitlement Programs? A Budget Impact Analysis. Value In Health 2010, 13: 893-902. PMID: 20950323, PMCID: PMC2999642, DOI: 10.1111/j.1524-4733.2010.00763.x.Peer-Reviewed Original ResearchConceptsHIV screeningEarly treatment goalsNew HIV casesFrequency of screeningBudget impact analysisTotal budget increasesHIV careAnnual incidenceHIV casesHIV prevalenceCDC estimatesUS CentersTreatment goalsBudget impactTreatment programDisease controlHIVTest characteristicsTreatment costsFinancial burdenCareScreeningSmall proportionProgram savingsFund care
2008
Modeling the Potential Impact of a Prescription Drug Copayment Increase on the Adult Asthmatic Medicaid Population
Bae SJ, Paltiel AD, Fuhlbrigge AL, Weiss ST, Kuntz KM. Modeling the Potential Impact of a Prescription Drug Copayment Increase on the Adult Asthmatic Medicaid Population. Value In Health 2008, 11: 110-118. PMID: 18237365, PMCID: PMC3476042, DOI: 10.1111/j.1524-4733.2007.00219.x.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAdultAge FactorsAnti-Asthmatic AgentsAsthmaCost SharingDrug PrescriptionsHealth Services AccessibilityHumansInsurance, Pharmaceutical ServicesMassachusettsMedicaidModels, EconometricNebulizers and VaporizersOutcome Assessment, Health CareState Health PlansTreatment RefusalUnited StatesConceptsFrequent acute exacerbationsAcute exacerbationCopayment increaseHealth outcomesPrescription drug copaymentsLikely health outcomesDrug nonadherenceCorticosteroid useAdult asthmaticsAcute eventDrug utilizationMedicaid populationDrug copaymentsMedicaid beneficiariesPrescription drugsCopaymentsReimbursement ratesFinancial burdenExacerbationTarget populationFirst yearNet savingsOutcomesPharmacyCommonwealth of Massachusetts